<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908687</url>
  </required_header>
  <id_info>
    <org_study_id>PLA201</org_study_id>
    <secondary_id>HHSO100200700031C</secondary_id>
    <nct_id>NCT00908687</nct_id>
  </id_info>
  <brief_title>A/H5N1/LT Dose Ranging Study</brief_title>
  <official_title>A Randomized Blinded, LT Dose-ranging Study to Assess the Immunogenicity and Safety of Different Doses of LT Adjuvant Patch Administered in Conjunction With Different Doses of Inactivated Influenza A/H5N1 Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercell USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Intercell USA, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, blinded, clinical trial. Up to 500 eligible subjects will be
      enrolled and randomized in a 1:2:2:1:2:2 ratio into one of six groups, and vaccinated in this
      study. Subjects will receive an intramuscular injection of the influenza A/H5N1 (low or high
      dose) on Day 0 with or without a patch (low or high dose).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the Proportion of Subjects in Each Dose Group Achieving Seroconversion and Seroprotection for HI Antibody Titer Through Day 28.</measure>
    <time_frame>Day 28</time_frame>
    <description>Seroconversion is defined as either 1) baseline HI titer &lt; 1:10 and a post-vaccination HI titer ≥ 1:40, or 2) baseline HI titer ≥ 1:10 and a minimum four-fold rise. Seroprotection is defined as a post-vaccination HI antibody titer ≥ 1:40.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of A/H5N1 Vaccine IM Injection With and Without an LT Adjuvant Patch</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of a 100μg LT Patch</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Treatment Group HI Responses Against US FDA Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines (May 2007) and EMA CPMP/BWP/214/96 Criteria for Immunogenicity</measure>
    <time_frame>Day 28</time_frame>
    <description>The percent of subjects achieving seroconversion for HI antibody titer should meet or exceed 40%
The percent of subjects achieving an HI antibody titer ≥ 1:40 should meet or exceed 70%
Geometric mean titer (GMT) fold increase &gt; 2.5</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adjuvanticity Evaluation: Compare HI Immune Responses Achieved by Antigen and Adjuvant Combinations With Antigen Alone Groups.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cross-clade HI Antibody Titer Measurement: Compare the Heterologous HI Antibody Responses to the A/Indonesia/05/2005 (Clade 2.1) Strain of the H5N1 Virus.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Pandemic Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1: 30 µg HA, no LT patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A/H5N1 Vaccine 30 µg HA i.m. on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 30 µg HA + 50 µg LT patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: 30 µg HA + 100 µg LT patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: 45 µg HA, no LT patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A/H5N1 Vaccine 45 µg HA i.m. on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: 45 µg HA + 50 µg LT patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6: 45 µg HA + 100 µg LT patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1</intervention_name>
    <description>A/H5N1 Low Dose</description>
    <arm_group_label>Group 1: 30 µg HA, no LT patch</arm_group_label>
    <arm_group_label>Group 2: 30 µg HA + 50 µg LT patch</arm_group_label>
    <arm_group_label>Group 3: 30 µg HA + 100 µg LT patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1</intervention_name>
    <description>A/H5N1 High Dose</description>
    <arm_group_label>Group 4: 45 µg HA, no LT patch</arm_group_label>
    <arm_group_label>Group 5: 45 µg HA + 50 µg LT patch</arm_group_label>
    <arm_group_label>Group 6: 45 µg HA + 100 µg LT patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LT Adjuvant Patch</intervention_name>
    <description>LT Adjuvant Patch Low Dose</description>
    <arm_group_label>Group 2: 30 µg HA + 50 µg LT patch</arm_group_label>
    <arm_group_label>Group 5: 45 µg HA + 50 µg LT patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LT Adjuvant Patch</intervention_name>
    <description>LT Adjuvant Patch High Dose</description>
    <arm_group_label>Group 3: 30 µg HA + 100 µg LT patch</arm_group_label>
    <arm_group_label>Group 6: 45 µg HA + 100 µg LT patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male or females 18 to 49 years of age (inclusive)

          -  Signed Informed Consent

          -  Women who are not post-menopausal or surgically sterile must have a negative serum or
             urine pregnancy test at screening and within 24 hours of vaccination with
             understanding (through informed Consent process) to not become pregnant over the
             duration of the study, and must agree to employ an effective form of birth control for
             the duration of the study. Acceptable forms of birth control are: abstinence, hormonal
             contraceptives (oral, injectable, implant, patch, ring), double-barrier contraceptives
             (condom or diaphragm, with spermicide) and IUD

        Exclusion Criteria:

          -  Clinically significant laboratory abnormalities at screening

          -  Abnormalities at physical examination [as determined by the Toxicity Grading Scale
             (grade 1-4)]

          -  Known allergies to any component of the vaccine

          -  Known egg protein allergy

          -  Known allergies to adhesives

          -  Known disturbance of coagulation

          -  Participated in research involving investigational product within 45 days before
             planned date of vaccination

          -  Donated or received blood or blood products such as plasma within the past 45 days

          -  Received any licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks
             (for live vaccines) prior to planned date of vaccination

          -  Ever received investigational enterotoxigenic E. coli, or LT (R192G) or NasalFlu,
             Berna Biotech Ltd

          -  Ever received cholera toxin or vaccine (e.g. Orochol, Dukoral)

          -  History of abdominal surgery (excluding C-Section, hysterectomy, cosmetic surgery,
             liposuction, appendectomy, cholecystectomy, ventral hernia repair, and other surgeries
             not pertaining to gastrointestinal problems) or history of, or recent acute
             gastrointestinal (GI) illness

          -  Previous vaccination with a pandemic vaccine or previous proven contact with A/H5N1
             wild type virus (contact with an individual with laboratory-confirmed A/H5N1 infection
             or contact with an animal which died as a result of A/H5N1 infection)

          -  Recent or regular use of oral, topical or injected steroid medications within 45 days
             prior to vaccination

          -  Use of immunosuppressive systemic steroid medications including inhaled steroids
             within three months prior to vaccination

          -  Comorbid conditions or treatments that are immunosuppressive, including cancer,
             diabetes, and end-stage renal disease, as determined by the Investigator

          -  Positive serology for HIV-1, HIV-2, HBsAg, or HCV

          -  History of severe atopy

          -  Medical history of acute or chronic skin disease at vaccination area

          -  Active skin allergy

          -  Signs of acute skin infection, sunburn or skin abnormalities at the vaccination area
             including fungal infections, severe acne, active contact dermatitis, or a history of
             keloid formation

          -  Hirsute (significant amount of hair) at vaccination area

          -  Artificial tanning (UV radiation) over the duration of the study including the
             screening period

          -  Visible tattoos or marks (tattoos/scars) at the vaccination area that would prevent
             appropriate dermatologic monitoring of the vaccination site

          -  Fever greater than or equal to 38.0°C (100.4°F) at the time of planned vaccination

          -  Suspicion of or recent history (within one year of planned vaccination) of alcohol or
             substance abuse

          -  Women who are pregnant or breastfeeding

          -  Acute illness at screening or at baseline

          -  Ever had a serious reaction to prior influenza vaccination

          -  Developed a neurological disorder (such as Guillian Barré syndrome) in the six weeks
             following a previous influenza vaccination

          -  Medical history of achlorhydria

          -  Employee of the investigational site or sponsor

          -  History of employment in bird or poultry industries or considerable exposure to birds
             (e.g. poultry or avian veterinarians, bird breeders, poultry butchers and/or culler,
             etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Sheldon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miami Research Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solano Clinical Research</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clinical Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.intercell.com</url>
    <description>Intercell Homepage</description>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2009</study_first_submitted>
  <study_first_submitted_qc>May 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2009</study_first_posted>
  <results_first_submitted>January 30, 2014</results_first_submitted>
  <results_first_submitted_qc>January 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 13, 2014</results_first_posted>
  <last_update_submitted>January 30, 2014</last_update_submitted>
  <last_update_submitted_qc>January 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: 30 µg HA, no LT Patch</title>
          <description>A/H5N1 Vaccine 30 µg HA i.m. on Day 0
A/H5N1: A/H5N1 Low Dose</description>
        </group>
        <group group_id="P2">
          <title>Group 2: 30 µg HA + 50 µg LT Patch</title>
          <description>A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
A/H5N1: A/H5N1 Low Dose
LT Adjuvant Patch: LT Adjuvant Patch Low Dose</description>
        </group>
        <group group_id="P3">
          <title>Group 3: 30 µg HA + 100 µg LT Patch</title>
          <description>A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
A/H5N1: A/H5N1 Low Dose
LT Adjuvant Patch: LT Adjuvant Patch High Dose</description>
        </group>
        <group group_id="P4">
          <title>Group 4: 45 µg HA, no LT Patch</title>
          <description>A/H5N1 Vaccine 45 µg HA i.m. on Day 0
A/H5N1: A/H5N1 High Dose</description>
        </group>
        <group group_id="P5">
          <title>Group 5: 45 µg HA + 50 µg LT Patch</title>
          <description>A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
A/H5N1: A/H5N1 High Dose
LT Adjuvant Patch: LT Adjuvant Patch Low Dose</description>
        </group>
        <group group_id="P6">
          <title>Group 6: 45 µg HA + 100 µg LT Patch</title>
          <description>A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
A/H5N1: A/H5N1 High Dose
LT Adjuvant Patch: LT Adjuvant Patch High Dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="102"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="98"/>
                <participants group_id="P6" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="99"/>
                <participants group_id="P4" count="47"/>
                <participants group_id="P5" count="94"/>
                <participants group_id="P6" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>safety population: all subjects with signed Informed Consent who have received investigational product</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: 30 µg HA, no LT Patch</title>
          <description>A/H5N1 Vaccine 30 µg HA i.m. on Day 0
A/H5N1: A/H5N1 Low Dose</description>
        </group>
        <group group_id="B2">
          <title>Group 2: 30 µg HA + 50 µg LT Patch</title>
          <description>A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
A/H5N1: A/H5N1 Low Dose
LT Adjuvant Patch: LT Adjuvant Patch Low Dose</description>
        </group>
        <group group_id="B3">
          <title>Group 3: 30 µg HA + 100 µg LT Patch</title>
          <description>A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
A/H5N1: A/H5N1 Low Dose
LT Adjuvant Patch: LT Adjuvant Patch High Dose</description>
        </group>
        <group group_id="B4">
          <title>Group 4: 45 µg HA, no LT Patch</title>
          <description>A/H5N1 Vaccine 45 µg HA i.m. on Day 0
A/H5N1: A/H5N1 High Dose</description>
        </group>
        <group group_id="B5">
          <title>Group 5: 45 µg HA + 50 µg LT Patch</title>
          <description>A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
A/H5N1: A/H5N1 High Dose
LT Adjuvant Patch: LT Adjuvant Patch Low Dose</description>
        </group>
        <group group_id="B6">
          <title>Group 6: 45 µg HA + 100 µg LT Patch</title>
          <description>A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
A/H5N1: A/H5N1 High Dose
LT Adjuvant Patch: LT Adjuvant Patch High Dose</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="102"/>
            <count group_id="B4" value="50"/>
            <count group_id="B5" value="98"/>
            <count group_id="B6" value="100"/>
            <count group_id="B7" value="500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.9" spread="9.7"/>
                    <measurement group_id="B2" value="29.8" spread="9.6"/>
                    <measurement group_id="B3" value="31.3" spread="10.4"/>
                    <measurement group_id="B4" value="30.5" spread="8.7"/>
                    <measurement group_id="B5" value="28.1" spread="8.2"/>
                    <measurement group_id="B6" value="30.8" spread="8.3"/>
                    <measurement group_id="B7" value="30.1" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="64"/>
                    <measurement group_id="B7" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assess the Proportion of Subjects in Each Dose Group Achieving Seroconversion and Seroprotection for HI Antibody Titer Through Day 28.</title>
        <description>Seroconversion is defined as either 1) baseline HI titer &lt; 1:10 and a post-vaccination HI titer ≥ 1:40, or 2) baseline HI titer ≥ 1:10 and a minimum four-fold rise. Seroprotection is defined as a post-vaccination HI antibody titer ≥ 1:40.</description>
        <time_frame>Day 28</time_frame>
        <population>Primary Immunogenicity Evaluable Population (PIEP): all subjects who were consented, randomized, received the assigned treatment, had HI assay results at all the following time points: baseline (Day 0), Day 21 and Day 28, and did not have any major protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 30 µg HA, no LT Patch</title>
            <description>A/H5N1 Vaccine 30 µg HA i.m. on Day 0
A/H5N1: A/H5N1 Low Dose</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 30 µg HA + 50 µg LT Patch</title>
            <description>A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
A/H5N1: A/H5N1 Low Dose
LT Adjuvant Patch: LT Adjuvant Patch Low Dose</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 30 µg HA + 100 µg LT Patch</title>
            <description>A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
A/H5N1: A/H5N1 Low Dose
LT Adjuvant Patch: LT Adjuvant Patch High Dose</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 45 µg HA, no LT Patch</title>
            <description>A/H5N1 Vaccine 45 µg HA i.m. on Day 0
A/H5N1: A/H5N1 High Dose</description>
          </group>
          <group group_id="O5">
            <title>Group 5: 45 µg HA + 50 µg LT Patch</title>
            <description>A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
A/H5N1: A/H5N1 High Dose
LT Adjuvant Patch: LT Adjuvant Patch Low Dose</description>
          </group>
          <group group_id="O6">
            <title>Group 6: 45 µg HA + 100 µg LT Patch</title>
            <description>A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
A/H5N1: A/H5N1 High Dose
LT Adjuvant Patch: LT Adjuvant Patch High Dose</description>
          </group>
        </group_list>
        <measure>
          <title>Assess the Proportion of Subjects in Each Dose Group Achieving Seroconversion and Seroprotection for HI Antibody Titer Through Day 28.</title>
          <description>Seroconversion is defined as either 1) baseline HI titer &lt; 1:10 and a post-vaccination HI titer ≥ 1:40, or 2) baseline HI titer ≥ 1:10 and a minimum four-fold rise. Seroprotection is defined as a post-vaccination HI antibody titer ≥ 1:40.</description>
          <population>Primary Immunogenicity Evaluable Population (PIEP): all subjects who were consented, randomized, received the assigned treatment, had HI assay results at all the following time points: baseline (Day 0), Day 21 and Day 28, and did not have any major protocol deviations</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="96"/>
                <count group_id="O6" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HI Seroconversion Rates</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" lower_limit="22.2" upper_limit="50.5"/>
                    <measurement group_id="O2" value="47.4" lower_limit="37.2" upper_limit="57.8"/>
                    <measurement group_id="O3" value="37.6" lower_limit="28.2" upper_limit="47.8"/>
                    <measurement group_id="O4" value="53.1" lower_limit="38.3" upper_limit="67.5"/>
                    <measurement group_id="O5" value="50.5" lower_limit="40.1" upper_limit="61.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="39.5" upper_limit="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HI Seroprotection Rates</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" lower_limit="22.2" upper_limit="50.5"/>
                    <measurement group_id="O2" value="47.4" lower_limit="37.2" upper_limit="57.8"/>
                    <measurement group_id="O3" value="37.6" lower_limit="28.2" upper_limit="47.8"/>
                    <measurement group_id="O4" value="55.1" lower_limit="40.2" upper_limit="69.3"/>
                    <measurement group_id="O5" value="53.7" lower_limit="43.2" upper_limit="64.0"/>
                    <measurement group_id="O6" value="50.0" lower_limit="39.5" upper_limit="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of A/H5N1 Vaccine IM Injection With and Without an LT Adjuvant Patch</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of a 100μg LT Patch</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Treatment Group HI Responses Against US FDA Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines (May 2007) and EMA CPMP/BWP/214/96 Criteria for Immunogenicity</title>
        <description>The percent of subjects achieving seroconversion for HI antibody titer should meet or exceed 40%
The percent of subjects achieving an HI antibody titer ≥ 1:40 should meet or exceed 70%
Geometric mean titer (GMT) fold increase &gt; 2.5</description>
        <time_frame>Day 28</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjuvanticity Evaluation: Compare HI Immune Responses Achieved by Antigen and Adjuvant Combinations With Antigen Alone Groups.</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cross-clade HI Antibody Titer Measurement: Compare the Heterologous HI Antibody Responses to the A/Indonesia/05/2005 (Clade 2.1) Strain of the H5N1 Virus.</title>
        <time_frame>6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1: 30 µg HA, no LT Patch</title>
          <description>A/H5N1 Vaccine 30 µg HA i.m. on Day 0
A/H5N1: A/H5N1 Low Dose</description>
        </group>
        <group group_id="E2">
          <title>Group 2: 30 µg HA + 50 µg LT Patch</title>
          <description>A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
A/H5N1: A/H5N1 Low Dose
LT Adjuvant Patch: LT Adjuvant Patch Low Dose</description>
        </group>
        <group group_id="E3">
          <title>Group 3: 30 µg HA + 100 µg LT Patch</title>
          <description>A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
A/H5N1: A/H5N1 Low Dose
LT Adjuvant Patch: LT Adjuvant Patch High Dose</description>
        </group>
        <group group_id="E4">
          <title>Group 4: 45 µg HA, no LT Patch</title>
          <description>A/H5N1 Vaccine 45 µg HA i.m. on Day 0
A/H5N1: A/H5N1 High Dose</description>
        </group>
        <group group_id="E5">
          <title>Group 5: 45 µg HA + 50 µg LT Patch</title>
          <description>A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
A/H5N1: A/H5N1 High Dose
LT Adjuvant Patch: LT Adjuvant Patch Low Dose</description>
        </group>
        <group group_id="E6">
          <title>Group 6: 45 µg HA + 100 µg LT Patch</title>
          <description>A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
A/H5N1: A/H5N1 High Dose
LT Adjuvant Patch: LT Adjuvant Patch High Dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="87" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="85" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vaccination site erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="54" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="53" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vaccination site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="58" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="55" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vaccination site hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vaccination site edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="33" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vaccination site induration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vaccination site eccymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vaccination site pruritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="54" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head Clinical Development</name_or_title>
      <organization>Valneva Austria GmbH</organization>
      <phone>0043120620 ext 0</phone>
      <email>info@valneva.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

